Akums Drugs and Pharmaceuticals (NSE:AKUMS) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AKUMS Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
39 GF Score
Price ₹660.60
! 7 Warning Signs
View Full Analysis

What is Akums Drugs and Pharmaceuticals LT-Debt-to-Total-Asset?

Akums Drugs and Pharmaceuticals NSE:AKUMS -0.59% 39 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates NSE:AKUMS with a GF Score™ of 39/100. The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Akums Drugs and Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

Akums Drugs and Pharmaceuticals's long-term debt to total assets ratio declined from Mar. 2025 (0.02) to Mar. 2026 (0.01). It may suggest that Akums Drugs and Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Akums Drugs and Pharmaceuticals  (NSE:AKUMS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Akums Drugs and Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Akums Drugs and Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Akums Drugs and Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals LT-Debt-to-Total-Asset Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.01 0.06 0.04 0.02 0.01

Akums Drugs and Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.00 0.02 0.00 0.01
NSE:AKUMS
39GF Score
Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akums Drugs and Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Akums Drugs and Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=768.44/54469.65
=0.01

Akums Drugs and Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=768.44/54469.65
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Akums Drugs and Pharmaceuticals and its competitors.
Is Akums Drugs and Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Akums Drugs and Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.01. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' LT-Debt-to-Total-Asset compare to ZTS?
Akums Drugs and Pharmaceuticals' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Akums Drugs and Pharmaceuticals and its competitors. Akums Drugs and Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current LT-Debt-to-Total-Asset of 0.01. The current LT-Debt-to-Total-Asset is 0.01. Akums Drugs and Pharmaceuticals' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akums Drugs and Pharmaceuticals Business Description

Other Exchanges 544222:India
Address Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
39GF Score

Get the complete analysis for NSE:AKUMS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹660.60
Price